BOSTON — In this Healio Video Perspective from Eyecelerator@ASCRS, Richard Small, CEO of Neurotech Pharmaceuticals, gives an update on encapsulated cell therapy for the extended treatment of retinal diseases.
Following two successful phase 3 studies, Neurotech is preparing to submit a license application for the cell therapy platform to the FDA “very soon.”
Small also discusses the company’s efforts to build on its infrastructure and manufacturing capabilities ahead of the submission.